Increased cancer risk in a cohort of patients with acromegaly in Israel

in Endocrine-Related Cancer
Authors:
Hadar Duskin-Bitan Institute of Endocrinology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, and School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
Clalit Health Services, Tel Aviv, Israel

Search for other papers by Hadar Duskin-Bitan in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-1721-1360
,
Alon Perez Clalit Health Services, Tel Aviv, Israel

Search for other papers by Alon Perez in
Current site
Google Scholar
PubMed
Close
,
Doron Netzer Clalit Health Services, Tel Aviv, Israel
Adelson School of Medicine Ariel University, Ariel, Israel

Search for other papers by Doron Netzer in
Current site
Google Scholar
PubMed
Close
,
Arnon D Cohen Clalit Health Services, Tel Aviv, Israel

Search for other papers by Arnon D Cohen in
Current site
Google Scholar
PubMed
Close
,
Doron Comaneshter Clalit Health Services, Tel Aviv, Israel

Search for other papers by Doron Comaneshter in
Current site
Google Scholar
PubMed
Close
,
Tanya Beckenstein Clalit Health Services, Tel Aviv, Israel

Search for other papers by Tanya Beckenstein in
Current site
Google Scholar
PubMed
Close
,
Shlomit Yaron Schneider Children’s Medical Center of Israel, Petach Tikva and Siaal Research Center for Family Medicine and Primary Care, Department of Family Medicine, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel

Search for other papers by Shlomit Yaron in
Current site
Google Scholar
PubMed
Close
,
Zaina Adnan Division of Endocrinology and Metabolism, Clalit Health Services, Haifa and Western Galilee District, and Department of Endocrinology, Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel

Search for other papers by Zaina Adnan in
Current site
Google Scholar
PubMed
Close
,
Yaron Rudman Institute of Endocrinology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, and School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Yaron Rudman in
Current site
Google Scholar
PubMed
Close
,
Hiba Masri Iraqi Institute of Endocrinology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, and School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Hiba Masri Iraqi in
Current site
Google Scholar
PubMed
Close
, and
Ilan Shimon Institute of Endocrinology, Rabin Medical Center – Beilinson Hospital, Petach Tikva, and School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

Search for other papers by Ilan Shimon in
Current site
Google Scholar
PubMed
Close

Correspondence should be addressed to H Duskin-Bitan: Hadarda@clalit.org.il
Restricted access
Rent on DeepDyve

Sign up for journal news

The association between acromegaly and cancer had been assessed mainly in population studies with inconsistent results. The objective of this study was to investigate the risk of cancer in a large cohort of patients with acromegaly compared with matched controls. The comprehensive computerized database of the largest healthcare provider organization in Israel was searched for patients diagnosed with acromegaly in 2000–2021. All diagnoses were qualitatively validated. Patients were individually matched 1:5 with a control group for age, sex and socioeconomic status. Clinical and outcome data were collected from medical files. The final cohort consisted of 470 patients (54% male) with acromegaly and 2,330 control subjects. The mean age at diagnosis was 53 years, and the mean duration of follow-up after diagnosis was 10.4 years. The prevalence of solid malignancies was 21.3% in the acromegaly group and 14.8% in the control group (OR 1.6, 95% CI 1.2–2.0). Patients with acromegaly had a higher rate of thyroid cancer (2.8 vs 0.6%; OR 5.1, CI 2.3–11.0) and a tendency for a higher risk of colorectal cancer (3.6 vs 2.8%; OR 1.3, CI 0.7–2.2), prostate cancer (2.8 vs 1.7%; OR 1.6, CI 0.8–3.1) and renal cancer (1.5 vs 0.8%; OR 1.8, CI 0.8–4.4), but not hematological malignancies. They also had a higher mortality rate (21.3 vs 15.7%; OR 1.5, CI 1.1–1.9). In conclusion, the higher prevalence of malignant solid tumors in patients with acromegaly compared with control subjects suggests that periodic screening for early detection of solid cancers may be considered in this patient population.

 

  • Collapse
  • Expand
  • Arnardóttir S , Järås J , Burman P , et al. 2022 Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur J Endocrinol 186 329339. (https://doi.org/10.1530/EJE-21-0729)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Boguszewski CL & Boguszewski MCDS 2019 Growth hormone's links to cancer. Endocr Rev 40 558574. (https://doi.org/10.1210/er.2018-00166)

  • Bolfi F , Neves AF , Boguszewski CL , et al. 2018 Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179 5971. (https://doi.org/10.1530/EJE-18-02550)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chesnokova V , Zonis S , Apostolou A , et al. 2021 Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage. Cell Rep 37 110068. (https://doi.org/10.1016/j.celrep.2021.110068)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Dal J , Leisner MZ , Hermansen K , et al. 2018 Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab 103 21822188. (https://doi.org/10.1210/jc.2017-02457)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Deodati A , Ferroli BB & Cianfarani S 2014 Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis. Growth Horm IGF Res 24 105111. (https://doi.org/10.1016/j.ghir.2014.02.001)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Esposito D , Ragnarsson O , Granfeldt D , et al. 2018 Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 178 459469. (https://doi.org/10.1530/EJE-18-0015)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Esposito D , Ragnarsson O , Johannsson G , et al. 2020 Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol 182 523531. (https://doi.org/10.1530/EJE-20-0019)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Esposito D , Ragnarsson O , Johannsson G , et al. 2021 Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study. J Clin Endocrinol Metab 106 34873496. (https://doi.org/10.1210/clinem/dgab560)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Falch CM , Olarescu NC , Bollerslev J , et al. 2023 Trends in incidence and mortality risk for acromegaly in Norway: a cohort study. Endocrine 80 152159. (https://doi.org/10.1007/s12020-022-03275-6)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fleseriu M , Barkan A , Del Pilar Schneider M , et al. 2022 Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary 25 296307. (https://doi.org/10.1007/s11102-021-01198-5)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Giustina A , Biermasz N , Casanueva FF , et al. 2024 Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27 722. (https://doi.org/10.1007/s11102-023-01360-1)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Holdaway IM , Bolland MJ & Gamble GD 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159 8995. (https://doi.org/10.1530/EJE-08-0267)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kasuki L , Maia B & Gadelha MR 2022 Acromegaly and colorectal neoplasm: an update. Front Endocrinol 13 924952. (https://doi.org/10.3389/fendo.2022.924952)

  • Kauppinen-Mäkelin R , Sane T , Välimäki MJ , et al. 2010 Increased cancer incidence in acromegaly – a nationwide survey. Clin Endocrinol 72 278279. (https://doi.org/10.1111/j.1365-2265.2009.03619.x)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Maione L , Brue T , Beckers A , et al. 2017 Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol 176 645655. (https://doi.org/10.1530/EJE-16-1064)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Mercado M , Gonzalez B , Vargas G , et al. 2014 Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99 44384446. (https://doi.org/10.1210/jc.2014-2670)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Petroff D , Tönjes A , Grussendorf M , et al. 2015 The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry. J Clin Endocrinol Metab 100 38943902. (https://doi.org/10.1210/jc.2015-2372)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Renehan AG , Zwahlen M , Minder C , et al. 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 13461353. (https://doi.org/10.1016/S0140-6736(04)16044-3)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Steuerman R , Shevah O & Laron Z 2011 Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol 164 485489. (https://doi.org/10.1530/EJE-10-0859)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Swerdlow AJ , Cooke R , Beckers D , et al. 2017 Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab 102 16611672. (https://doi.org/10.1210/jc.2016-2046)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Terzolo M , Reimondo G , Berchialla P , et al. 2017 Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr Relat Cancer 24 495504. (https://doi.org/10.1530/ERC-16-0553)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ucan B , Kizilgul M , Karci AC , et al. 2021 The prevalence of cancer and its relation to disease activity in patients with acromegaly: two centers' experience. Endocr Pract 27 5155. (https://doi.org/10.4158/EP-2020-0398)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wolinski K , Stangierski A , Dyrda K , et al. 2017 Risk of malignant neoplasms in acromegaly: a case-control study. J Endocrinol Investig 40 319322. (https://doi.org/10.1007/s40618-016-0565-y)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wu JC , Huang WC , Chang HK , et al. 2020 Natural history of acromegaly: incidences, re-operations, cancers, and mortality rates in a national cohort. Neuroendocrinology 110 977987. (https://doi.org/10.1159/000505332)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Xiao T , Jiao R , Yang S , et al. 2023a Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study. Endocrine 82 368378. (https://doi.org/10.1007/s12020-023-03447-y)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Xiao Z , Xiao P , Wang Y , et al. 2023b Risk of cancer in acromegaly patients: an updated meta-analysis and systematic review. PLoS One 18 e0285335. (https://doi.org/10.1371/journal.pone.0285335)

    • PubMed
    • Search Google Scholar
    • Export Citation